|
| 36996147 | Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS. | PLoS One | 2023 |
| 37397388 | A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study. | Front Oncol | 2023 |
| 34739582 | Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer. | Cancer Chemother Pharmacol | 2022 |
| 36029310 | Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics. | Cancer Chemother Pharmacol | 2022 |
| 35012962 | Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. | Life Sci Alliance | 2022 |
| 35042701 | Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients. | Drug Metab Dispos | 2022 |
| 33108504 | Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. | Cancer Chemother Pharmacol | 2021 |
| 33914350 | Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin. | J Clin Pharmacol | 2021 |
| 34075384 | Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization. | medRxiv | 2021 |
| 30090974 | Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer. | Clin Pharmacokinet | 2019 |
| 28094348 | Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. | Pharmacogenomics J | 2018 |
| 29974200 | Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of <sup>14</sup>C-plitidepsin. | Cancer Chemother Pharmacol | 2018 |
| 29883879 | Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine. | J Pharm Biomed Anal | 2018 |
| 30251598 | Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. | J Psychopharmacol | 2018 |
| 28592191 | Influence of two variants of CYP450 oxidoreductase on the stable dose of acenocoumarol in a Spanish population. | Pharmacogenomics | 2017 |
| 29048184 | Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy. | Exp Clin Psychopharmacol | 2017 |
| 26977927 | A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. | PLoS One | 2016 |
| 24861353 | Limited sampling strategies for tacrolimus exposure (AUC0-24) prediction after Prograf(®) and Advagraf(®) administration in children and adolescents with liver or kidney transplants. | Transpl Int | 2014 |
| 24821595 | Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. | J Antimicrob Chemother | 2014 |
| 23138399 | Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery. | Pediatr Res | 2013 |
| 23427051 | A preliminary model to avoid the overestimation of sample size in bioequivalence studies. | Drug Res (Stuttg) | 2013 |
| 23532479 | Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. | Clin Infect Dis | 2013 |
| 23249875 | Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. | Pharmacogenet Genomics | 2013 |
| 23111422 | Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. | Pharmacogenet Genomics | 2013 |
| 22371894 | Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. | Antimicrob Agents Chemother | 2012 |
| 22911785 | An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. | PLoS One | 2012 |
| 21288825 | Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. | J Infect Dis | 2011 |
| 20139798 | ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. | Pharmacogenet Genomics | 2010 |
| 20218903 | Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. | Clin Chem Lab Med | 2010 |
| 19225447 | Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. | Clin Pharmacol Ther | 2009 |
| 19238117 | In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. | Pharmacogenet Genomics | 2009 |
| 18680690 | [General concepts and study methods in pharmacogenetics]. | Enferm Infecc Microbiol Clin | 2008 |
| 17559351 | ADME pathway approach for pharmacogenetic studies of anti-HIV therapy. | Pharmacogenomics | 2007 |
| 15761068 | Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers. | J Antimicrob Chemother | 2005 |
| 12698301 | Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. | Eur J Clin Pharmacol | 2003 |